

SCIENCE

<http://www.aaas.org>

Published by the American Association for the Advancement of Science (AAAS), *Science* serves its readers as a forum for the presentation and discussion of important issues related to the advancement of science, including the presentation of minority or conflicting points of view, rather than by publishing only material on which a consensus has been reached. Accordingly, all articles published in *Science*—including editorials, news and comment, and book reviews—are signed and reflect the individual views of the authors and not official points of view adopted by the AAAS or the institutions with which the authors are affiliated.

The American Association for the Advancement of Science was founded in 1848 and incorporated in 1874. Its objectives are to further the work of scientists, to facilitate cooperation among them, to foster scientific freedom and responsibility, to improve the effectiveness of science in the promotion of human welfare, to advance education in science, and to increase public understanding and appreciation of the importance and promise of the methods of science in human progress.

Membership/Circulation

Director: Michael Spinella
Deputy Director: Marlene Zendell
Member Services: Mary Curry, *Supervisor*; Pat Butler, Helen Williams, Laurie Baker, *Representatives*
Marketing: Dee Valencia, *Manager*; Jane Pennington, *Europe Manager*; Hilary Baar, *Assistant Manager*; Angela Mumeka, *Coordinator*
Research: Renuka Chander, *Manager*
Business and Finance: Robert Smariga, *Manager*; Kevin Bullock, Nina Araujo de Kobes, *Coordinators*
Science Member Services
Danbury, CT: 800-731-4939
Washington, DC: 202-326-6417
Other AAAS Programs: 202-326-6400

Advertising and Finance

Associate Publisher: Beth Rosner
Advertising Sales Manager: Susan A. Meredith
Recruitment Advertising Manager: Janis Crowley
Business Manager: Deborah Rivera-Wienhold
Finance: Randy Yi, *Senior Analyst*; Shawn Williams, *Analyst*
Marketing: John Meyers, *Manager*; Allison Pritchard, *Associate*
Traffic: Carol Maddox, *Manager*; Amber Haslacker, *Sales Associate*
Recruitment: Terri Seiter Azie, *Assistant Manager*; Celeste Miller, Bethany Ritchey, Nancy Hicks, *Sales*; Debbie Cummings, *European Sales*
Reprints: Ordering/Billing, 800-407-9191; Corrections, 202-326-6501
Electronic Media: David Gillikin, *Manager*; Christine Pierpoint, *Internet Production Specialist*; Pamela Sams, *Internet Production Associate*
Permissions: Lincoln Richman
Exhibits Coordinator: Arlene Ennis
PRODUCT ADVERTISING SALES: **East Coast/E. Canada:** Richard Teeling, 201-904-9774, FAX 201-904-9701 • **Midwest/Southeast:** Elizabeth Mosko, 312-665-1150, FAX 312-665-2129 • **West Coast/W. Canada:** Neil Boylan, 415-673-9265, FAX 415-673-9267 • **UK, Scandinavia, France, Italy, Belgium, Netherlands:** Andrew Davies, (44) 1-457-838-519, FAX (44) 1-457-838-898 • **Germany/Switzerland/Austria:** Tracey Peers, (44) 1-260-297-530, FAX (44) 1-260-271-022 • **Japan:** Masahiko Yoshikawa, (3) 3235-5961, FAX (3) 3235-5852
RECRUITMENT ADVERTISING SALES: **US:** 202-326-6532, FAX 202-289-6742 • **Europe:** Debbie Cummings, +44 (0) 1223-302067, FAX +44 (0) 1223-576208 • **Australia/New Zealand:** Keith Sandell, (61) 02-922-2977, FAX (61) 02-922-1100
Send materials to *Science* Advertising, 1200 New York Avenue, NW, Washington, DC 20005.

Information for Contributors appears on pages 93–94 of the 5 January 1996 issue. Editorial correspondence, including requests for permission to reprint and reprint orders, should be sent to 1200 New York Avenue, NW, Washington, DC 20005.

Science World Wide Web address: <http://www.aaas.org>
Other Internet addresses: science_editors@aaas.org (for general editorial queries); science_letters@aaas.org (for letters to the editor); science_reviews@aaas.org (for returning manuscript reviews); membership@aaas.org (for member services); science_classifieds@aaas.org (for submitting classified advertisements); science_advertising@aaas.org (for product advertising)

LETTERS

Cell blocks

Research funds from the Tobacco Council are said to be “crucial to furthering biomedical research.” A pending decision to sell U.S. mercury stockpiles could “come back to haunt us” in the form of pollution. Confidence is expressed that “guidelines and regulations can be crafted” that adequately answer ethical questions surrounding research that uses samples from tissue banks. (Right, tissue storage at the U.S. Armed Forces Institute of Pathology.) How the hippocampus in the brain changes with age, as reflected by memory loss and by (debatably) the death of neurons, is discussed.



Tobacco Council and Research

In contrast to the statement by Brown University's Paul Calabresi (26 Apr., p. 493) in the special news report by Jon Cohen “Tobacco money lights up a debate” (26 Apr., p. 488) about research funding by the Council for Tobacco Research (CTR), this funding agency provides a “no strings attached” source of peer-reviewed funding in amounts often not obtainable from non-profit private funding agencies. This source of funding is crucial to furthering biomedical research by allowing young investigators to start a research program and enabling established investigators to begin new projects. Thus, the money is used to expand basic disease-related research, which is not different from the government using tobacco tax revenues to support socially significant programs.

To question the morality of using money from tobacco products to further disease-related research is to beg the larger question, What is the responsibility of private industry to contribute to funding basic research in an era of ever-contracting federal support? Why is there no “Council for Pharmaceutical Research” to support basic biomedical studies that are the foundation of the pharmaceutical and biotechnology industries? Although large technology-based corporations claim to have bottom-line considerations that do not allow them to invest in risky long-term basic research endeavors, it is clear from the CTR example that, when corporations see an advantage to supporting such research, funds can and will be made available. Perhaps it is time for the biomedical research community to make clear to other members of the private sector that there are broad advantages to contributing greater financial

support to the basic research that provides the technologies and insights from which the profits of their industries derive.

Finally, it is noteworthy that several research institutions refuse to allow their investigators to apply for CTR funding. In contrast to their high moral position, one wonders if a low indirect cost rate (15%) plays a role in their eschewing these awards.

Allan Mufson

David Scott

*Department of Immunology,
Jerome H. Holland Laboratory,
American Red Cross,
15601 Crabbs Branch Way,
Rockville, MD 20855, USA*

Mercury Stockpile

With great environmental and economic naiveté, the U.S. Department of Defense (DOD) is considering selling its mercury stockpile—60% of the world's supply. The sales would thwart scientific, regulatory, and industrial efforts to protect human and ecological health by limiting mercury release to the environment.

Individual states have long worked with industries, utilities, and the U.S. Environmental Protection Agency (EPA) to reduce, collect, and recycle mercury in industrial products and processes. European nations have taken similar actions. Sweden will phase out most mercury uses by the year 2000 and is considering permanent storage to remove mercury from global commerce (1).

The actions are in response to rising environmental mercury contamination, notably in lake fish from remote regions of